Insilico Medicine

Insilico Medicine is an artificial intelligence–driven drug discovery company that applies generative AI and machine learning across the full drug development pipeline, from target identification through clinical candidate selection. The company has built a reputation as one of the most prominent pure-play AI biotech firms, attracting major pharmaceutical partnerships as evidence that AI-generated drug candidates can advance through meaningful development milestones.

The company's commercial profile has risen sharply with a series of high-value licensing deals. A collaboration with Servier valued at up to $888 million and a research and licensing agreement with Eli Lilly valued at up to $2.75 billion place Insilico among the most heavily capitalized AI drug-discovery players. The company has also completed a Hong Kong IPO, giving it public-market visibility alongside its growing portfolio of pharmaceutical partnerships.

Beyond oncology, Insilico Medicine has staked out a distinctive position in longevity science, establishing what it describes as the industry's first dedicated Longevity Board. This focus reflects the company's founding orientation around aging biology and signals an ambition to apply its AI platform to the underlying mechanisms of age-related disease, not just individual drug targets.